1. After reading an overly long introduction (2.5 pages!) with about 30 references the I find out that the paper is about describing the uptake of PCSK9 mabs in a period of 1.25 years, with a little sprinkle of patient descriptions. Besides shortening the introduction to a more manageable number of pages (hopefully quickening the pace for the readership), couldn't the authors do something a bit more interesting with these data.
The fact the that the number of patients increases after market approval seems hardly surprising. To give a suggestion, instead of going on and on about the LDL-C hypothesis, the mechanism of PCSK9 inhibition, the trial evidence (all of which doesn't play a role in the current paper), perhaps the authors could use the introduction to discuss the ECS and ACC guidelines on PCSK9 prescription?
Personally I would find it interesting to compare the Danish prescription practice (as recorded in this data) to the ECS and ACC guidelines. This could bring the needed flavor to a rather bland dish.
2. The authors repeatedly state that, barring FH patient, they have included all patient who were prescribed PCSK9 inhibition in Denmark. Trusting that this is the case I am puzzled at the use of significant testing in this paper, for example in Table 2 between patients with and without "triple-treatment" and without (on a side note this research question wasn't stated anywhere in the introduction).
If the target population of this study is Danish non-FH patient who were prescribed PCSK9 inhibition in 2016 and the first quartile of 2017, then the sample as recorded in this study and the target population are one and the same. So in other words the authors are in the luxurious position that there is no sampling variation and have their hands on data from the entire population. However, this also means that all metrics using sample variation such as p-value or confidence intervals (not actually used, but mentioning it nevertheless) are incorrect and lead to fallacious conclusion as stating that there were no "significant" difference between the groups of table 2 (for example).
Instead of using p-value and its perceived define quality, I would ask the authors to please perform some independent thinking and describe which between group difference they feel is noteworthy. As an example, I thought it was interesting that in the triple treatment group only 5% had heart failure vs 12.8 in the non triple group.
Minor comments:
-. In table 2 what is the meaning of these inequalities '<3' and why don't the have percentages e.g., < 3/59*100 \approx 5.
-. In the introduction "and no increased risk of demention" could you include confidence intervals with this? Just because something isn't significant (in the p < 0.05 sense) doesn't mean it can be used as proof for an absence of effect, perhaps the sampling variance was simply very larger (i.e., uncertainty).
-. It is probably clearer to speak about a history of stroke instead of stroke, the latter might be interpreted as an outcome.
-. Figure 1 isn't a box plot, it's a barplot.
-. Nice Venn diagram.
-. Appendix 2, could you use anything but the qqplot2 default colours -> https://ggplot2.tidyverse.org/reference/scale_brewer.html
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Reviewer 1
Revision point 1:
The authors should comment on the high percentage of patients treated with simvastatin Response: We agree that it would be helpful to comment on the high number of patients treated with Simvastatin.
Page 17 line 7. After revision: "The infrequent use of Rosuvastatin was primarily due to a protecting marketing patent making Rosuvastatin more expensive than Atorvastatin and preferencing Atorvastatin as the first choice of potent statins in Denmark. Simvastatin is primarily indicated in the process of overcoming side effects of potent statin treatment in order to reach a maximum tolerated LLT and as primary prophylaxis treatment of CVD. In our cohort, 36% of patients were receiving simvastatin, which most likely indicates attempts of titrating to maximum tolerated dosage of statin when considering the strict national criteria for medicine subsidy regarding PCSK9i treatment."
Revision point 2:
The low percentage of use of Rosuvastatin in the cohort should also be discussed.
Response: Thank you for pointing this out. This is discussed in the new inserted paragraph above.
Revision point 3:
Were there any patients treated with simvastatin 80 mg?
Response: Thank you for this comment. This is all statins and not only simvastatin. Although the maximum dosage of Simvastatin is 80mg it is most often prescribed in 40mg daily. The group of "Statins" also includes Atorvastatin, which is more likely to prescribed in 80mg dosage.
Furthermore, we are in an ongoing investigating of how many patients actually did receive Simvastatin 80mg and we can add this data when ready Revision point 4: Are there any restrictions in the use of PCSK9 in Denmark?
Response: Yes there is restrictions for prescribing PCSK9i in Denmark. We have added the following to clear this up Addition to introduction page 5 line 17 After revision: "The European Society of Cardiology (ESC) and The American College of Cardiology (ACC) guidelines [12, 13] have endorsed PCSK9i treatment in patients at high risk and very high risk of future cardiovascular events. Partly due to the high cost of PCSK9i, most countries have established national guidelines and committees to approve a prior authorization application for medicine subsidy in the individual patient. In Denmark, PCSK9i treatment was reimbursed and as such PCSK9i were approved for medication subsidy in patients with very high risk of future CVD (i.e. patients with a history of acute coronary syndrome, acute myocardial infarction, atherosclerotic polyvascular disease, or diabetes mellitus with IHD) and in patients with high risk of future CVD (i.e. patients with a history of stable angina pectoris or diabetes mellitus with either target organ damage, peripheral atherosclerotic artery disease, transitory cerebral ischemia, or ischemic cerebral infarction) who despite maximally tolerated lipid lowering treatment (LLT) require further reduction of LDL-C levels. Established cut off LDL-C values were 3.0 mmol/L (115 mg/dL) and 3.5 mmol/L (135 mg/dL) in the very high-risk patients and high-risk patients respectively (appendix). Statin intolerance in these patients would also be approved for subsidy when treatment with at least three types of statin starting in low dosages titrated to maximum tolerated dosage and ezetimibe and bile acid sequestrant had been attempted prior to PCSK9i initiation. The ESC and ACC guidelines further endorse additional clinical criteria i.e. patients with a history of isolated peripheral atherosclerotic artery disease, isolated ischemic cerebral infarction, or diabetes mellitus with marked hypertension or hypercholesterolemia and at different LDL-C measurement cut off values. In these patients, however, there is a lack of treat to target trials and the effects of intensified LDL-C lowering is not with thorough evidence [14, 15] ." Revision point 5: Are PCSK9 reimbursed in Denmark?
Response: Yes, PCSK9i are reimbursed in Denmark. Please find an answer for this excellent question in the paragraph above.
Reviewer 2:
Revision point 1: The authors could use the introduction to discuss the ECS and ACC guidelines on PCSK9 prescription? Personally, I would find it interesting to compare the Danish prescription practice to the ECS and ACC guidelines.
Response:
We also find this to be very helpful to compare international guidelines with the Danish guidelines so we have added a new paragraph in the introduction page 5 line 17. The content of the new paragraph can be found below:
Page 5 line 17 "The European Society of Cardiology (ESC) and The American College of Cardiology (ACC) guidelines [12, 13] have endorsed PCSK9i treatment in patients at high risk and very high risk of future cardiovascular events. Partly due to the high cost of PCSK9i, most countries have established national guidelines and committees to approve a prior authorization application for medicine subsidy in the individual patient. In Denmark, PCSK9i were approved for subsidy in patients with very high risk of future CVD (i.e. patients with a history of acute coronary syndrome, acute myocardial infarction, atherosclerotic polyvascular disease, or diabetes mellitus with IHD) and in patients with high risk of future CVD (i.e. patients with a history of stable angina pectoris or diabetes mellitus with either target organ damage, peripheral atherosclerotic artery disease, transitory cerebral ischemia, or ischemic cerebral infarction) who despite maximally tolerated lipid lowering treatment (LLT) require further reduction of LDL-C levels. Established cut off LDL-C values were 3.0 mmol/L (115 mg/dL) and 3.5 mmol/L (135 mg/dL) in the very high-risk patients and high-risk patients respectively (appendix). Statin intolerance in these patients would also be approved for subsidy when treatment with at least three types of statin starting in low dosages titrated to maximum tolerated dosage and ezetimibe and bile acid sequestrant had been attempted prior to PCSK9i initiation. The ESC and ACC guidelines further endorse additional clinical criteria i.e. patients with a history of isolated peripheral atherosclerotic artery disease, isolated ischemic cerebral infarction, or diabetes mellitus with marked hypertension or hypercholesterolemia) and at different LDL-C measurement cut off values. In these patients, however, there is a lack of treat to target trials and the effects of intensified LDL-C lowering is not with thorough evidence [14, 15] .
Addition to discussion: After revision: "Economic considerations can also help explain the modified and individually formed national guidelines for PCSK9i initiation. Committing fully to the criteria for PCSK9i initiation stated in the ESC or ACC guidelines would probably not be realistic for any countries' medical expenditures resulting in many patients being rejected for medicine subsidy and patients with certain clinical characteristics being favorited [41] or over-treated." Addition to discussion: After revision: "Despite having been endorsed by guidelines for patients with many different kinds of atherosclerotic CVD, 66% of the patients initiated on PCSK9i had a history of IHD (appendix table 2). The large randomized trials investigating the effects of intensified LLT [7, 9, 10, [26] [27] [28] [29] Response: Thank you for this point. We have added the following to the introduction After revision: Page 6 line 18 "Given the novelty of PCSK9i and the difference in national and international guidelines, we do not know the exact prevalence, the clinical characteristics, concurrent medication, or the attempts of double and triple LLT in patients initiated on PCSK9i.
In the present study, we wanted to assess the total number of patients initiated on PCSK9i in the first quarter (Q1) of 2016 to the Q1 of 2017 with a description of the clinical patient characteristics, comorbidities, medication use, concurrent LLT in these patients. Furthermore, we wanted to compare these parameters in patients attempted on triple LLT and patients on single or double LLT."
Revision point 3:
The use of significant testing in this paper, for example in Table 2 between patients with and without "triple-treatment" Response: We agree, that using significance testing in this particular study is irrelevant. We have deleted the p-values in Table 2 .
Revision point 4:
It was interesting that in the triple treatment group only 5% had heart failure vs 12.8 in the non-triple group.
Response: We also found this very interesting and discussed this more extensively in the revised manuscript After revision page 17 line 15: "We found, that patients on dual LLT were more prone to have heart failure than patients attempted on triple LLT prior to PCSK9i initiation. The treating physicians managing PCSK9i initiations could possibly be more susceptible to intensify the LLT and lower the LDL-C as fast and effective as possible to reduce the risk of future cardiovascular events in the more frail patients with greater risk of mortality, i.e. patients with verified heart failure. Although patients were initiated according to both national and international guidelines, perhaps certain other clinical traits might influence both physicians and committees approving medicine subsidy [25] . Patient demographics and concurrent medication use did not differ noteworthy in patients having received triple LLT and patients not having received triple LLT."
Revision point 5:
In table 2 what is the meaning of these inequalities '<3' and why don't the have percentages e.g., < 3/59*100 \approx 5.
Response: Thanks for pointing this out. In Denmark it is not allowed to report the specific number if less than three patients fulfill the particular clinical characteristic.
After revision: Page 9 line 15 in methods section: The ethical legislation in Denmark does not permit the reporting of clinical patient characteristics in less than three patients.
Revision point 6:
In the introduction "and no increased risk of demention" could you include confidence intervals with this? Just because something isn't significant (in the p < 0.05 sense) doesn't mean it can be used as proof for an absence of effect, perhaps the sampling variance was simply very larger (i.e., uncertainty).
Thank you for providing this excellent point. We have now deleted this section.
Revision point 7: Figure 1 is not a box plot, it is a barplot After revision: Changed Figure 1 Legend from box-plot to Bar plot.
Revision point 8:
